Brought to you by 
Shire gets European rights to Salix's balsalazide
15 Aug 2011
Executive Summary
Shire Pharmaceuticals licensed exclusive rights in several European countries to the ulcerative colitis drug balsalazide from Salix Pharmaceuticals. AstraZeneca had previously licensed rights in those markets, but cancelled the agreement late last year.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets European rights to Salix's balsalazide
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice